AQSTAquestive Therapeutics, Inc.

Healthcare

$4.00-42% 1Y

$4.00

$2.9552 weeks$7.01

Price

-42%1Y

End-of-day closes, not the intraday tick.

A mixed picture: the questions disagree

Quality shaky, a flag to check, growing in the filings, the market undecided.

RyuScore 11 of 100: see how it is built

P/En/a

Market value$501.4M

1 year-42%

5 years+3.2%

Charts

As reported to the SEC, without any scoring.

Aquestive Therapeutics, Inc. (AQST) reported revenue of $14M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 71% and net loss of $23M. For the full year FY2025, revenue was $45M (−23% year on year) and net income −$84M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 19, 2026On October 15, 2026, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”), in connection with its periodic review of corporate governance matters, approved and adopted amended and restated bylaws (the "Amended Bylaws"), effective October 15, 2026.Charter/bylaw amendment or fiscal-year change · Form 8-K
Oct 14, 2026On October 13, 2026, Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") entered into a license agreement (the "License Agreement") with Eton Pharmaceuticals, Inc. ("Eton") pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film (the "Product") for …Material agreement entered · Form 8-K
Sep 29, 2026On September 29, 2026, Aquestive Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has elected Richard J. Daly as a director of the Company, effective October 14, 2026.Director or officer change · Form 8-K